Thread: Bull Case on $FSRV

$FSRV is a great investment due to strong balance sheet, incredible growth in both earnings and revenue, and serve a competitive niche within this fintech market. I am very excited to be apart of this, undervalued, long term investment opportunity:

What does Katapult do?

They’re a fintech lending, e-commerce focused, service that allows nonprime customers to borrow money and purchase durable goods such as: Fridge’s, Tables, Couches, etc
Why they are competitive?

Some consumers with little to no credit often times don’t get approved, and it can be costly. Katapult leverages AI and ML to allocate money to them CHEAPER and faster than ever before.
Has this been profitable?

They have both grown revenue AND EBITDA at astounding rates. They hit profitability this year and grew 171% YoY. They project they will have a CAGR of EBITDA and Net Income at 75% 🤯🤯

This is a profit and growth monster, an investors dream!
Can they maintain this growth?

Lending isn’t a new service, and neither is leveraging AI/ML. But Katapult’s customer segment is niche, as nobody else wants to do it. They stand in their own quadrant, providing a long runway for niche growth.
Do they have a plan to continue growing?

They’re very forward looking and also a younger company. They still have not penetrated their total market or brought awareness to their solution for their total market. They have a clear strategy to do this and diversify their product.
How does the overall balance sheet look?

This is one where I’ve seen a few investors stumble up on when they see that big ‘liabilities’ number. But one must understand what “revolving line of credit” means. Once you do, one can assume they’re using the liquidity to lend more.
Are they a good buy at today’s price?

YES! 1,000x over yes. Affirm, their competitors/partner, will be going the IPO route soon and will, without a doubt, be over valued. With a high CAGR, attractive EBITDA valuation, and attractive revenue valuation. This is a buy.
Conclusion: $FSVR aka Katapult provides a very rare, high growth (both revenue and profit) opportunity that is nearly the holy grail of SPAC‘s. At today’s valuations, it’s still a screaming buy. The biggest risk at the moment is managements ability to continue to handle the
riskier investments they are making on subprime borrowers. They are also, obviously, using borrowed cash to lend to other people. This is a risk, as some people may not be able to it pay back and this is a balancing act.

However, this risk can be mitigated through appropriate
execution of their set in place frame work and strategy moving forward.

More from Trading

You May Also Like

My top 10 tweets of the year

A thread 👇

https://t.co/xj4js6shhy


https://t.co/b81zoW6u1d


https://t.co/1147it02zs


https://t.co/A7XCU5fC2m
@franciscodeasis https://t.co/OuQaBRFPu7
Unfortunately the "This work includes the identification of viral sequences in bat samples, and has resulted in the isolation of three bat SARS-related coronaviruses that are now used as reagents to test therapeutics and vaccines." were BEFORE the


chimeric infectious clone grants were there.https://t.co/DAArwFkz6v is in 2017, Rs4231.
https://t.co/UgXygDjYbW is in 2016, RsSHC014 and RsWIV16.
https://t.co/krO69CsJ94 is in 2013, RsWIV1. notice that this is before the beginning of the project

starting in 2016. Also remember that they told about only 3 isolates/live viruses. RsSHC014 is a live infectious clone that is just as alive as those other "Isolates".

P.D. somehow is able to use funds that he have yet recieved yet, and send results and sequences from late 2019 back in time into 2015,2013 and 2016!

https://t.co/4wC7k1Lh54 Ref 3: Why ALL your pangolin samples were PCR negative? to avoid deep sequencing and accidentally reveal Paguma Larvata and Oryctolagus Cuniculus?